Anti-Lipocalin 13 (Lipocalin-13, LCN13, Obp2a, Odorant-binding Protein 2a)

LCN­13 (Lipocalin 13, also Odorant­binding protein 2a) is a secreted, 26­28kD member of the LCN family, calycin superfamily of molecules. Its name is derived from Greek, and denotes the fact that lipocalins are known to be "fat­wrapping", or fat binding proteins that interact with small lipophilic molecules within a central cavity. LCN­13 is expressed by hepatocytes and smooth muscle cells. It is known to have antidiabetogenic effects, including the suppression of hepatic glucose production, the uptake of circulating glucose by adipocytes, and the induction of fatty acid oxidation by liver, possibly by stimulating CPT1alpha production. Mouse LCN­13 is synthesized as a 176 amino acid (aa) precursor that contains a 19aa signal sequence and a 157aa mature region. Although no splice forms have been reported for LCN­13 to date, a smaller, presumably proteolytically processed 23­26kD isoform has been noted on SDS­PAGE. Mature mouse LCN­13 shares 69% and 39% aa sequence identity with rat LCN­13 and human odorant­binding protein 2b, respectively. Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 0.5ug/ml, Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.